angiotensin
convert
enzym
ma
axi
repres
promis
target
induc
stroke
neuroprotect
explor
strokeinduc
chang
express
activ
endogen
angiotensin
convert
enzym
system
compon
spragu
dawley
rat
evalu
clinic
feasibl
treatment
target
axi
may
act
synergi
strokeinduc
chang
also
test
neuroprotect
effect
diminazen
acetur
angiotensin
convert
enzym
activ
administ
system
poststrok
amongst
rat
underw
experiment
ischem
stroke
angiotensin
convert
enzym
activ
cerebr
cortex
striatum
increas
hour
stroke
serum
angiotensin
convert
enzym
activ
decreas
within
post
stroke
rebound
reach
higher
baselin
level
poststrok
treatment
follow
stroke
systemicallyappli
diminazen
result
decreas
infarct
volum
improv
neurolog
function
without
appar
increas
cerebr
blood
flow
central
infus
ma
receptor
antagonist
result
larger
infarct
volum
diminazenetr
rat
central
infus
angiotensin
convert
enzym
inhibitor
alon
worsen
neurolog
function
dynam
alter
protect
angiotensin
convert
enzym
pathway
follow
stroke
suggest
may
favor
therapeut
target
inde
signific
neuroprotect
result
poststrok
angiotensin
convert
enzym
activ
like
via
ma
signal
blood
flowindepend
manner
find
suggest
stroke
therapeut
target
angiotensin
convert
enzym
ma
axi
may
interact
cooper
endogen
strokeinduc
chang
lend
promis
studi
neuroprotect
agent
stroke
diseas
hypertens
remain
lead
modifi
risk
factor
devast
realiti
year
mani
million
peopl
worldwid
lead
caus
death
disabl
renin
angiotensin
system
ra
hold
promis
potenti
target
novel
stroke
therapi
especi
recent
discoveri
counterregulatori
arm
ra
exert
opposit
effect
signal
via
activ
receptor
includ
angiotensin
ang
receptor
ma
ang
form
angiotensin
ii
ang
ii
action
angiotensin
convert
enzym
character
action
variou
patholog
expand
view
therapeut
potenti
small
molecul
activ
pathway
signific
research
effort
field
neuroprotect
stroke
therapi
aim
discoveri
novel
treatment
may
administ
salvag
penumbr
tissu
uniqu
vulner
collaps
ma
pathway
highlight
promis
target
induct
stroke
neuroprotect
proven
efficaci
reduc
infarct
size
improv
neurolog
function
preclin
model
ischem
hemorrhag
stroke
stroke
neuroprotect
demonstr
young
age
anim
method
activ
axi
includ
direct
intracerebroventricular
administr
ang
deliveri
endotheli
progenitor
cell
neuron
overexpress
pharmacolog
activ
axi
recent
becom
feasibl
identif
diminazen
acetur
trade
name
activ
shown
given
intracerebroventricular
infus
stroke
diminazen
reduc
infarct
size
rat
effect
revers
coadministr
ma
antagonist
import
consider
continu
studi
therapeut
effect
ang
ma
axi
stroke
character
chang
occur
endogen
compon
system
stroke
absenc
target
intervent
recent
report
express
protect
axi
alter
follow
stroke
rat
cerebr
cortex
rostral
ventrolater
medulla
although
unknown
whether
activ
level
affect
whether
accompani
chang
deleteri
angiotensin
convert
enzymeangiotensin
iiangiotensin
ii
type
receptor
aceang
axi
object
test
whether
compon
ra
includ
ma
pathway
alter
rat
follow
stroke
assess
hypothesi
poststrok
system
administr
activ
diminazen
rat
would
result
neuroprotect
descript
experiment
procedur
refer
materi
method
pleas
see
http
hyperahajournalsorg
access
onlineonli
data
supplement
ischem
stroke
induct
describ
experi
method
result
significantli
increas
activ
cerebr
cortex
ipsilater
stroke
compar
control
activ
level
shamoper
rat
ischemia
fig
along
increas
ipsilater
striatum
compar
sham
contralater
striatum
fig
activ
contralater
cortic
sampl
also
significantli
increas
compar
respect
sham
level
fig
activ
level
cerebr
cortex
striatum
return
sham
level
fig
b
signific
chang
mrna
level
ipsilater
cortex
either
follow
ischemia
fig
stroke
result
initi
minor
decreas
activ
rat
serum
measur
poststrok
compar
normal
prestrok
level
follow
signific
rebound
increas
three
day
poststrok
fig
thought
exert
neuroprotect
effect
part
via
convers
ang
ii
ang
subsequ
bind
signal
ang
receptor
ma
therefor
assess
impact
stroke
mrna
level
ma
also
neuroprotect
find
signific
differ
follow
mcao
fig
addit
protect
arm
ra
compon
classic
aceang
pathway
evalu
compar
sham
increas
ace
mrna
level
ipsilater
cortex
chang
mrna
fig
expect
also
observ
increas
mrna
level
marker
astrocyt
activ
marker
activ
microglia
fig
evalu
level
tumor
necrosi
enzym
tace
also
name
enzym
form
solubl
cleav
membranebound
form
via
sheddas
activ
sampl
ipsilater
cortex
found
signific
increas
tace
mrna
activ
poststrok
rel
sham
fig
interestingli
although
tace
mrna
express
level
significantli
differ
sham
stroke
group
tace
activ
significantli
decreas
sampl
ischem
cortex
time
point
serum
tace
activ
differ
sham
stroke
group
poststrok
data
shown
character
strokeinduc
chang
ma
express
neuron
brain
cell
employ
immunohistochem
stain
label
neun
ma
immunoreact
cell
repres
fluoresc
micrograph
fig
show
neun
ma
stain
within
stroke
penumbra
sham
stroke
rat
poststrok
semiquantit
analysi
immunofluoresc
stain
show
percentag
fraction
area
neun
ma
immunoposit
stain
ipsilater
cerebr
cortex
significantli
decreas
compar
sham
rat
cerebr
cortex
fig
c
observ
increas
activ
ipsilater
cerebr
cortex
follow
stroke
repres
promis
target
induc
stroke
neuroprotect
previous
report
prestrok
activ
central
use
diminazen
result
signific
neuroprotect
administ
intracerebroventricular
infus
prior
mcao
test
clinic
relev
treatment
protocol
describ
experi
method
employ
poststrok
intraperiton
inject
drug
vehicl
follow
mcao
time
overlap
endogen
strokeinduc
chang
ma
axi
fig
identifi
maxim
efficaci
dose
diminazen
poststrok
peripher
administr
perform
set
doserespons
experi
rat
stroke
result
larg
infarct
volum
among
vehicletr
versu
shamoper
rat
compar
vehicletr
control
infarct
volum
significantli
decreas
poststrok
intraperiton
inject
diminazen
dose
mgkg
mgkg
fig
accompani
strokeinduc
neurolog
deficit
significantli
attenu
mgkg
diminazen
fig
c
data
shown
data
present
fig
demonstr
poststrok
administr
diminazen
mgkg
intraperiton
result
significantli
higher
level
serum
activ
poststrok
similar
though
signific
increas
day
base
collect
result
find
intraperiton
administr
affect
level
baselin
blood
pressur
cerebr
blood
flow
cbf
fig
mgkg
dose
use
subsequ
experi
assess
masdepend
neuroprotect
induc
poststrok
intraperiton
diminazen
inject
chronic
coadminist
ma
antagonist
steril
salin
vehicl
via
intracerebroventricular
rout
blockad
central
ma
receptor
infus
rat
cotreat
poststrok
peripher
diminazen
result
significantli
larger
infarct
size
compar
salin
infus
fig
examin
role
endogen
central
stroke
infus
inhibitor
via
intracerebroventricular
rout
five
day
three
day
stroke
absenc
treatment
result
significantli
wors
neurolog
function
poststrok
without
significantli
increas
infarct
volum
fig
g
ang
vasodilatori
action
may
potenti
contribut
neuroprotect
induc
activ
test
effect
cbf
administ
diminazen
rat
neuroprotect
dose
mcao
poststrok
describ
experi
method
rel
cbf
increas
diminazin
stroke
compar
control
measur
laser
doppler
flowmetri
poststrok
fig
also
observ
increas
baselin
level
absolut
cbf
assess
microspher
inject
method
amongst
rat
chronic
treat
intracerebroventricular
infus
diminazen
fig
compar
salineinfus
rat
studi
aim
assess
endogen
poststrok
chang
within
ra
focu
activ
test
neuroprotect
efficaci
poststrok
activ
system
administr
diminazen
might
work
synergist
chang
endogen
ra
found
signific
increas
endogen
activ
express
within
ischem
cerebr
cortex
striatum
rat
first
hour
stroke
serum
activ
level
initi
decreas
follow
rebound
increas
stroke
level
immunoreact
ma
significantli
decreas
ischem
penumbra
mrna
level
deleteri
ra
compon
ace
increas
administr
poststrok
diminazen
result
signific
neuroprotect
well
increas
serum
activ
lastli
studi
effect
diminazen
cbf
suggest
protect
may
associ
increas
cerebr
perfus
increas
number
studi
indic
activ
ma
axi
neuroprotect
stroke
studi
provid
essenti
foundat
sever
limit
current
design
help
address
first
chang
express
activ
endogen
compon
pathway
brain
stroke
warrant
investig
recent
demonstr
increas
level
ang
ma
stroke
ischem
cerebr
cortex
rat
import
first
look
second
studi
transient
mcao
rat
examin
axi
compon
rostral
ventrolater
medulla
rvlm
show
slightli
differ
find
region
decreas
ang
ma
follow
stroke
light
find
result
show
increas
activ
ischem
cortex
fig
decreas
ma
immunoreact
fig
intrigu
reduct
immunoreact
ma
observ
penumbr
region
ischem
cortex
stroke
agre
find
rvlm
may
due
overal
decreas
penumbr
ma
cortic
neuron
immunostain
neuron
nuclear
marker
neun
decreas
time
point
fig
c
work
need
clarifi
variou
chang
other
observ
like
differ
stroke
model
transient
versu
perman
mcao
play
distinct
role
induct
ra
compon
data
show
increas
activ
cerebr
cortex
support
overal
consensu
stroke
activ
protect
axi
second
one
previou
studi
treatment
condit
start
stroke
onset
either
genet
modif
prestrok
administr
activ
compound
use
clinicallyrelev
protocol
chen
colleagu
first
util
poststrok
treatment
protocol
studi
neuroprotect
deliv
endotheli
progenitor
cell
without
prime
tail
vein
inject
start
hour
stroke
mice
cell
protect
even
absenc
prime
sinc
enhanc
benefici
effect
isol
effect
activ
ma
pathway
stroke
onset
unclear
administ
activ
peripher
inject
start
stroke
onset
allow
assess
therapeut
efficaci
set
overlap
favor
hour
treatment
window
deliveri
tissu
plasminogen
activ
human
stroke
victim
well
endogen
strokeinduc
chang
ra
fig
also
relev
system
fig
c
well
central
administr
diminazen
demonstr
neuroprotect
efficaci
intraven
drug
administr
prefer
rout
human
emerg
set
evid
indic
peripher
diminazen
cross
intact
blood
brain
barrier
set
stroke
wellcharacter
barrier
leaki
allow
mani
compound
cross
third
limit
previous
publish
studi
begin
address
involv
scarciti
data
describ
ma
axi
human
stroke
higher
level
found
among
patient
experienc
cardioembol
stroke
versu
stroke
subtyp
although
baselin
control
level
assess
comparison
also
shown
gene
polymorph
may
associ
increas
risk
stroke
serum
measur
protect
ra
compon
limit
direct
assess
human
serum
activ
hold
promis
clinic
marker
stroke
studi
first
assess
enzymat
activ
anim
serum
follow
stroke
fig
encourag
translat
potenti
anim
data
chang
follow
stroke
activ
rat
serum
fig
show
similar
pattern
chang
observ
preliminari
studi
use
human
serum
obtain
stroke
patient
unpublish
data
although
human
studi
treatment
target
ang
ma
axi
perform
stroke
shown
applic
recombin
human
healthi
volunt
welltoler
make
plausibl
idea
futur
studi
stroke
patient
sinc
recent
indic
diminazen
activ
shown
efficaci
treat
varieti
inflammatori
diseas
includ
stroke
first
show
poststrok
administr
small
molecul
activ
result
signific
neuroprotect
fig
importantli
recent
report
question
whether
diminazen
activ
show
effect
incub
vitro
recombin
ex
vivo
kidney
lysat
found
similar
result
unpublish
experi
use
recombin
human
lysat
cerebr
cortex
howev
assay
serum
activ
anim
receiv
system
diminazen
cours
sever
day
follow
stroke
reveal
signific
increas
serum
activ
fig
find
similar
studi
diminazen
myocardi
infarct
diminazen
may
increas
activ
vivo
period
time
andor
condit
diseas
stress
yet
undiscov
effect
transcript
translat
protein
modif
relat
molecul
regardless
observ
increas
activ
impli
increas
ang
gener
subsequ
ma
signal
result
poststrok
inject
diminazen
valid
data
show
significantli
wors
infarct
volum
coadministr
fig
vasodilatori
action
ang
suggest
contribut
neuroprotect
effect
stroke
data
indic
diminazen
increas
region
cbf
mcao
absolut
cbf
baselin
condit
fig
b
nonetheless
ang
may
still
act
increas
perfus
level
microcircul
way
detect
measur
cbf
potenti
mediat
effect
diminazen
specif
may
independ
reduc
inflamm
rule
contribut
neuroprotect
effect
observ
current
studi
limit
explor
neuroprotect
benefit
target
axi
acut
subacut
phase
ischem
stroke
remain
import
question
impact
treatment
longerterm
outcom
late
mortal
anticip
futur
studi
area
address
translationallyrelev
question
studi
examin
effect
stroke
induct
compon
classic
ra
report
ang
ii
level
increas
stroke
cortex
one
day
stroke
other
shown
ang
ii
upregul
ace
tace
decreas
express
might
account
chang
observ
one
day
poststrok
fig
fig
role
tace
sheddas
receiv
recent
attent
possibl
contribut
factor
develop
neurogen
hypertens
hypothes
tacemedi
shed
impair
brain
compensatori
activ
along
line
evid
studi
cell
cultur
show
ang
iiinduc
proteolyt
cleavag
membranebound
mediat
increas
activ
tace
accompani
increas
plasma
activ
presum
result
increas
find
show
significantli
increas
express
tace
mrna
cortex
fig
coincid
earli
rebound
increas
serum
activ
start
stroke
fig
suggest
brain
cleav
membran
may
move
circul
strokeinduc
blood
brain
barrier
breakdown
seem
unlik
complet
account
increas
serum
activ
day
stroke
level
brain
tace
activ
significantli
attenu
time
fig
explan
observ
poststrok
chang
serum
activ
level
fig
includ
alter
releas
solubl
membran
endotheli
cell
evid
suffici
posit
identifi
signal
process
could
initi
alter
shed
follow
stroke
seem
plausibl
ang
ii
shown
increas
tace
involv
anoth
explan
incorpor
bone
marrowderiv
hematopoiet
cell
potenti
sourc
solubl
atherosclerot
plaqu
express
cell
marker
endotheli
hematopoiet
progenitor
cell
evid
suggest
activ
mononuclear
cell
lead
increas
tace
could
result
increas
shed
activ
leukocyt
level
cell
peripher
blood
follow
stroke
human
may
follow
similar
pattern
observ
serum
activ
fig
initi
decreas
follow
rebound
increas
taken
togeth
find
suggest
shed
brain
endotheli
andor
activ
hematopoiet
cell
may
contribut
chang
serum
activ
follow
stroke
physiolog
relev
chang
serum
activ
clear
evid
seem
indic
close
link
activ
tace
regul
ang
ii
signal
refer
web
version
pubm
central
supplementari
materi
new
first
studi
character
activ
follow
stroke
test
noninvas
administr
activ
begin
stroke
clinicallyrelev
approach
relev
find
strokeinduc
chang
within
pathway
import
step
understand
way
best
target
use
potenti
stroke
treatment
discoveri
neuroprotect
give
activ
stroke
compel
evid
continu
studi
pathway
toward
clinic
applic
stroke
result
dynam
chang
activ
brain
serum
rat
poststrok
system
administr
activ
result
improv
infarct
size
neurolog
function
like
activ
ma
ang
receptor
hypertens
author
manuscript
avail
pmc
juli
